Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Bernstein lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $94 from $90 and maintained an Outperform rating on the shares. It noted that revenues of $875 million beat by 5%, while EPS of 46c missed by 16%, primarily due to the consensus not modeling Roctavian write-down. The firm further stated that the total revenue guidance missed by 6%, while EPS missed by 3%, with product sales guidance looking soft on Voxzogo and solid on Enzymes.

The rating update came after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q4 and full-year 2025 financial and operating results on February 23. Full year total revenues rose 13% year-over-year to $3.2 billion, led primarily by a 9% revenue growth for enzyme therapies and 26% revenue growth for VOXZOGO®. Total revenues for fiscal Q4 grew 17% year-over-year, led by 13% revenue growth for enzyme therapies and 31% revenue growth for VOXZOGO. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) also announced a definitive agreement to acquire Amicus Therapeutics, which is expected to considerably accelerate and diversify revenues.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.